Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non Operating Income (2016 - 2022)

Enanta Pharmaceuticals' Other Non Operating Income history spans 11 years, with the latest figure at $393000.0 for Q2 2022.

  • For Q2 2022, Other Non Operating Income fell 10.48% year-over-year to $393000.0; the TTM value through Jun 2022 reached -$782000.0, up 78.64%, while the annual FY2021 figure was -$27000.0, 118.12% down from the prior year.
  • Other Non Operating Income reached $393000.0 in Q2 2022 per ENTA's latest filing, up from $255000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $2.4 million in Q2 2019 to a low of -$5.3 million in Q3 2020.
  • Average Other Non Operating Income over 5 years is $225600.0, with a median of $393000.0 recorded in 2022.
  • Peak YoY movement for Other Non Operating Income: tumbled 108.79% in 2018, then soared 24050.0% in 2019.
  • A 5-year view of Other Non Operating Income shows it stood at -$58000.0 in 2018, then surged by 3679.31% to $2.1 million in 2019, then crashed by 67.39% to $677000.0 in 2020, then tumbled by 61.89% to $258000.0 in 2021, then surged by 52.33% to $393000.0 in 2022.
  • Per Business Quant, the three most recent readings for ENTA's Other Non Operating Income are $393000.0 (Q2 2022), $255000.0 (Q1 2022), and $258000.0 (Q4 2021).